Moderna Inc (MRNA) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

Total Cash From Operating Activities Chart for Moderna Inc

Moderna Inc (MRNA) operating cash flow for FY2025 was USD -1.9B. Moderna Inc's operating cash flow moved from USD -4.8M in 2014 to USD -1.9B in 2025 over 11 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$21.50B
Implied Share Price
$53.86
Enterprise Value
$17.90B
Revenue (TTM)
$2.23B
EBITDA
-$2.20B
Profit Margin
-141.43%
Trailing P/E
—
Forward P/E
23.04
Price/Book (MRQ)
3.22
Price/Sales (TTM)
9.65
EV/EBITDA
4.64
EV/Revenue
8.10
Dividend Yield
—
Book Value
$18.66
Free Cash Flow (FY2025)
-$2.06B
Free Cash Flow Yield
-9.60%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.